EGFR and cancer: Comparison of DepMap cancer cell line drug sensitivity data (Meyers and Bryan, 2017; Corsello et al., 2020) with exon 17b inclusion and exclusion junction expression revealed that exon 17b inclusion correlates with increased sensitivity to EGFR inhibitors, represented by a negative correlation with drug area under the curve (AUC; Fig. 2 C).